Sermorelin — GHRH(1-29) by Dragon Pharma
Sermorelin is Dragon Pharma's formulation of the synthetic GHRH analogue Sermorelin at 5mg per vial — a 29 amino acid peptide representing the biologically active N-terminal fragment of endogenous Growth Hormone-Releasing Hormone. It was the first GHRH analogue to receive FDA approval and remains the most physiologically conserved GHRH secretagogue available, producing pulsatile GH release through the same receptor pathway as the body's own GHRH.
Also searched as: Sermorelin 5mg, GHRH 1-29, Sermorelin acetate, Sermorelin Dragon Pharma, Geref equivalent.
What Is Sermorelin — GHRH(1-29) Explained
Endogenous GHRH is a 44 amino acid peptide (GHRH 1-44) secreted by the hypothalamus. Research in the 1980s demonstrated that only the first 29 amino acids (the N-terminal sequence, GHRH 1-29) are required for full biological activity at the GHRH receptor:
- Sermorelin = GHRH(1-29) — it contains the biologically active portion of the natural GHRH molecule
- The remaining 15 amino acids of native GHRH (positions 30-44) contribute to stability and binding kinetics in the body but are not required for receptor activation
- This shorter structure makes Sermorelin more susceptible to enzymatic degradation than modified analogues like Tesamorelin or CJC-1295 DAC — resulting in a very short half-life of approximately 10-20 minutes
- This extremely short half-life is both a limitation (requires precise dosing timing) and a feature (produces the most physiologically pulsatile GH pattern of any GHRH analogue)
Sermorelin's FDA History — The Most Clinically Validated GHRH
Sermorelin has a regulatory history no other GHRH analogue in this category can match:
- FDA approved in 1990 under the trade name "Geref" (Serono) for the diagnosis of GH deficiency in children — making it the first and only GHRH analogue approved for this indication
- The approval required clinical trials demonstrating both efficacy and safety in human subjects — creating a body of clinical data for Sermorelin that predates any other GHRH analogue in use today
- Geref was discontinued in the US in 2008 not due to safety concerns but due to commercial factors — availability shifted to compounding pharmacies and research peptide suppliers
- This FDA history means Sermorelin has more published human clinical data supporting its GH-stimulating activity than CJC-1295 no DAC or CJC-1295 DAC
Sermorelin vs Other GHRH Analogues — The Full Comparison
| Parameter | Sermorelin | CJC-1295 no DAC | CJC-1295 DAC | Tesamorelin |
|---|---|---|---|---|
| Structure | GHRH(1-29) | Modified GHRH(1-29) — 4 amino acid substitutions | GHRH(1-29) + DAC | Modified GHRH(1-44) |
| Half-life | ~10–20 min | ~30 min | ~6–8 days | ~26 min |
| DPP-IV resistance | Low — rapidly degraded | Moderate — 4 substitutions improve stability | High — albumin binding | Moderate — chemical modification |
| GH pattern | Most physiological pulse | Pulsatile | Sustained bleed | Pulsatile |
| Dosing frequency | 2–3× daily minimum | 2–3× daily | Once weekly | Once daily |
| FDA history | Approved 1990 (Geref) | None | None | Approved 2010 (Egrifta) |
| Clinical fat loss data | Limited | None | None | Phase III RCT |
Why Sermorelin's Ultra-Short Half-Life Is an Advantage for Physiological Protocols
Sermorelin's 10-20 minute half-life — shorter than any other GHRH analogue — produces the closest approximation to the body's natural GHRH secretion pattern:
- Natural GHRH is released in short bursts from the hypothalamus, immediately stimulating a GH pulse, then rapidly cleared — the pituitary "resets" between pulses
- Sermorelin's ultra-short action mimics this pattern most closely — each injection produces a sharp GH pulse that rises and falls within 1-2 hours, followed by complete clearance
- CJC-1295 no DAC (~30 min) and Tesamorelin (~26 min) are slightly more stable but produce a qualitatively similar pulsatile pattern
- CJC-1295 DAC (~6-8 days) departs most significantly from natural pulsatility, producing the sustained "GH bleed" pattern
- For users prioritising maximum physiological alignment with natural GH secretion patterns — particularly relevant for anti-aging protocols — Sermorelin is the most conservative choice
Effects and Benefits
- Pulsatile GH release closely mimicking the body's natural GHRH-driven secretion pattern
- Improved sleep quality — pre-sleep dosing amplifies the natural nocturnal GH pulse
- Body recomposition support through elevated GH and downstream IGF-1
- Anti-aging profile — most conservative GHRH approach for long-term wellness protocols
- No suppression of natural testosterone — does not require Post Cycle Therapy
- Longest clinical safety record of any GHRH analogue — FDA-approved 1990
Dosage and Administration
| Protocol | Dose | Frequency |
|---|---|---|
| Once daily (minimum) | 200–300 mcg | Before bed, fasted |
| Twice daily | 100–200 mcg each | Pre-bed + upon waking (fasted) |
| Three times daily | 100 mcg each | Pre-bed, waking, post-workout |
Sermorelin's very short half-life means it must be dosed more frequently than even CJC-1295 no DAC for comparable cumulative GH stimulation. Pre-sleep fasted dosing remains the most important injection. At 5mg per vial, dosing at 200mcg per injection provides 25 injections per vial — approximately 25 days at once-daily dosing or ~8 days at three-times-daily. Combine with a GHRP such as Ipamorelin for synergistic GH release 3-5× greater than either compound alone.
Sermorelin in Stack Protocols
- Anti-aging/wellness: Sermorelin alone or with Ipamorelin — most physiological, conservative long-term approach
- Body recomposition: Sermorelin + Ipamorelin + BPC-157 / TB-500 for combined GH and recovery support
- Fat loss focus: Tesamorelin is preferred over Sermorelin when visceral fat reduction is the primary goal, due to Tesamorelin's Phase III fat loss data
Reconstitution and Storage
Reconstitute with bacteriostatic water — add slowly along the vial wall and swirl gently. Store reconstituted vial refrigerated at 2-8°C for up to 28-30 days. Never freeze. Calculate reconstitution volume based on intended dose per injection.
"Sermorelin is the most conservative GHRH option in our peptide range — as GHRH(1-29), it is the closest available analogue to the body's own Growth Hormone-Releasing Hormone, with a clinical safety record dating to its FDA approval in 1990."
Stacking and Related Compounds
- Ipamorelin — ideal GHRP partner for Sermorelin; clean, selective GH pulse with no cortisol elevation
- Tesamorelin — more potent GHRH option with Phase III visceral fat data if fat loss is primary goal
- CJC-1295 DAC — for users wanting weekly injection convenience instead of daily dosing
- Dragontropin (HGH) — for users escalating from secretagogue-based to direct GH protocols
